
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+4
Dimerix (ASX:DXB) is a clinical-stage biopharmaceutical company with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. Dimerix lead clinical asset, DMX-200 (or QYTOVRA in some territories), is in Phase 3 trials as a treatment for focal segmental glomerulosclerosis (FSGS), a rare kidney disease
Biotechnology,drug development,chronic kidney disease,nephrology,in vitro screening,platform technology,clinical research,drug discovery,and diabetic kidney disease
Dimerix limited operates in the Pharmaceutical manufacturing industry.
Dimerix limited's revenue is < 1m
Dimerix limited has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.